Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $20.30

Shares of NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) have received an average rating of "Moderate Buy" from the eleven research firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $20.30.

A number of equities analysts have recently issued reports on the stock. Bank of America increased their price objective on shares of NeoGenomics from $18.00 to $19.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Benchmark cut shares of NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. Jefferies Financial Group began coverage on NeoGenomics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price objective on the stock. Finally, Needham & Company LLC restated a "buy" rating and set a $19.00 target price on shares of NeoGenomics in a research report on Friday, January 10th.

NeoGenomics Stock Up 1.6 %

Shares of NASDAQ NEO traded up $0.23 during mid-day trading on Friday, hitting $14.21. The company had a trading volume of 1,279,681 shares, compared to its average volume of 638,803. NeoGenomics has a 12 month low of $12.13 and a 12 month high of $19.11. The business's 50-day simple moving average is $16.68 and its 200-day simple moving average is $15.67. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.04. The company had revenue of $167.80 million for the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. NeoGenomics's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.06) EPS. As a group, research analysts anticipate that NeoGenomics will post -0.16 earnings per share for the current fiscal year.

Insider Activity at NeoGenomics

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the company's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now owns 37,129 shares of the company's stock, valued at approximately $570,301.44. This represents a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Institutional Trading of NeoGenomics

A number of large investors have recently made changes to their positions in the company. Versant Capital Management Inc lifted its stake in NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock valued at $30,000 after buying an additional 1,142 shares in the last quarter. Quarry LP acquired a new position in NeoGenomics in the 3rd quarter worth $40,000. Blue Trust Inc. increased its holdings in NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company's stock worth $46,000 after purchasing an additional 987 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of NeoGenomics in the 2nd quarter valued at about $57,000. Finally, KBC Group NV lifted its holdings in shares of NeoGenomics by 33.1% in the third quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock valued at $67,000 after purchasing an additional 1,127 shares in the last quarter. Institutional investors own 98.50% of the company's stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.